GlobeNewswire News Room·2025-07-17 19:13Core Viewpoint - A class action lawsuit has been filed against Biohaven Ltd. for alleged misleading statements regarding its drug candidates, potentially impacting investors who purchased securities during the specified period [1][5]. Group 1: Lawsuit Details - The class action lawsuit pertains to purchasers of Biohaven securities between March 24, 2023, and May 14, 2025 [1]. - Allegations include overstated regulatory prospects for the drug troriluzole and its efficacy for treating spinocerebellar ataxia and bipolar disorder, which may have negatively affected Biohaven's business and financial condition [5]. Group 2: Investor Information - Investors who purchased Biohaven securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can submit their information through the provided link or contact the law firm directly [3][6]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [4]. - The firm has recovered hundreds of millions of dollars for investors, with notable achievements in previous years, including over $438 million in 2019 [4].